MedTrace Logo

Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation

NCT00617513 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2008-05-29

No results posted yet for this study

Summary

The purpose of this study is to determine which dose of prucalopride is safe and effective in patients with chronic idiopathic constipation.

Hypothesis:

Prucalopride 1 and 2 mg are safe and effective for the treatment of chronic idiopathic constipation whereas 0,5 mg is a suboptimal dose.

Conditions

Interventions

DRUG

Prucalopride

0.5 mg once daily

OTHER

Placebo

o.d.

DRUG

Prucalopride

1 mg o.d.

DRUG

Prucalopride

2 mg o.d.

Sponsors & Collaborators

  • Movetis

    lead INDUSTRY

Principal Investigators

  • Marc Van Outryve, MD · Jan Palfijn Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-03-31
Primary Completion
1996-03-31
Completion
1996-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00617513 on ClinicalTrials.gov